Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
truxals
Synonyms :
chlorprothixene
Class :
Antipsychotic, antidepressant
Brand Name :
truxals
Synonyms :
chlorprothixene
Class :
Antipsychotic, antidepressant
Dosage Forms & StrengthsÂ
film coated, Tablet, OralÂ
50 mgÂ
15 mgÂ
A dose of 30-45 mg (2-3 tablets) 3 to 4 times a day. the daily dose should not exceed more than 600 mg
Dosage Forms & StrengthsÂ
film coated, Tablet, OralÂ
50 mgÂ
15 mgÂ
for children above 6 years, a dose of 15 to 30 mg (1-2 tablets) 3 to 4 times a day
Dosage Forms & StrengthsÂ
film coated, Tablet, OralÂ
50 mgÂ
15 mgÂ
Elderly patients, a dose of 15 to 30 mg (1-2 tablets) 3 to 4 times a day
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
may have an increased arrhythmogenic effect when combined with mequitazine
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with sulpiride
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
progestins could potentially intensify the Harmful/toxic effects of chlorprothixene
progestins could potentially intensify the Harmful/toxic effects of chlorprothixene
progestins could potentially intensify the Harmful/toxic effects of chlorprothixene
progestins could potentially intensify the Harmful/toxic effects of chlorprothixene
progestins could potentially intensify the Harmful/toxic effects of chlorprothixene
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
When chlorprothixene is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
When ponesimod is used together with acebutolol, this leads to enhanced risk or seriousness of bradycardia
When chlorprothixene is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When chlorprothixene is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
When emylcamate is used together with chlorprothixene, this leads to enhanced risk or seriousness of CNS depression
When chlorprothixene is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with chlorprothixene, this leads to enhanced risk or seriousness of CNS depression
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
When chlorprothixene is used in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
the anticholinergic effect of chlorprothixene may be enhanced by anticholinergic agents
the anticholinergic effect of chlorprothixene may be enhanced by anticholinergic agents
the anticholinergic effect of chlorprothixene may be enhanced by anticholinergic agents
the anticholinergic effect of chlorprothixene may be enhanced by anticholinergic agents
the anticholinergic effect of chlorprothixene may be enhanced by anticholinergic agents
chlorprothixene: it may increase the central nervous system depressant activities of tolperisone
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
it may increase the neurotoxic effect of antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
it may increase the risk of adverse effects of antipsychotic agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
Serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may increase the hypotensive effect of anti-hypertensives
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may increase the hypotensive effect when combined with Antipsychotic Agents
may have an increased neurotoxic effect when combined with antipsychotic agents
the therapeutic activity of calcium polycarbophyl may be decreased
When chlorprothixene is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
Actions and spectrum:Â
Actions of chlorprothixene:Â
Spectrum of Activity:Â
chlorprothixene is primarily used for the treatment of various psychotic disorders, including schizophrenia and other severe mental illnesses characterized by abnormal thinking and behaviour. It is effective in managing positive symptoms of schizophrenia, such as hallucinations and delusions.Â
Frequency not definedÂ
orthostatic hypotensionÂ
increased fatigueÂ
tachycardiaÂ
urinary disordersÂ
dry mouthÂ
hot flashesÂ
constipationÂ
LeukocytosisÂ
hemolytic anemiaÂ
agranulocytosisÂ
leukopeniaÂ
yellowness of skinÂ
increased photosensitivityÂ
itchingÂ
PhotodermatitisÂ
galactorrheaÂ
AmenorrheaÂ
gynecomastiaÂ
AgitationÂ
IrritabilityÂ
Black Box Warning:Â
There were no specific black box warnings for chlorprothixene.Â
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Comorbidities:Â
Pregnancy consideration: pregnancy category CÂ
Lactation: excreted into breast milk: yes Â
Pregnancy category:Â
Pharmacology:Â
chlorprothixene is an antipsychotic medication belonging to the thioxanthene class. Its pharmacology involves interactions with various receptors and neurotransmitter systems in the brain. As a potent dopamine D2 receptor antagonist, it reduces dopamine activity, alleviating positive symptoms of psychotic disorders such as schizophrenia, like hallucinations and delusions.
Additionally, chlorprothixene exhibits antagonistic effects on serotonin 5-HT2A receptors, potentially contributing to its antipsychotic activity and improving negative symptoms. The drug’s antagonism at alpha-adrenergic receptors leads to sedative effects and reduced anxiety. It also possesses antihistamine properties due to its H1 receptor antagonism, causing sedation and contributing to weight gain. However, the anticholinergic effects arising from muscarinic receptor antagonism can result in side effects like dry mouth and constipation. Â
Pharmacodynamics:Â
Pharmacokinetics:Â
AbsorptionÂ
chlorprothixene is well absorbed when taken orally. However, its absorption can be variable and is influenced by factors such as food intake, individual differences in metabolism, and the specific formulation of the drug.Â
DistributionÂ
After absorption, chlorprothixene is distributed throughout the body via the bloodstream. It crosses blood-brain barrier and enter the central nervous system (CNS), where it exerts its antipsychotic effects. chlorprothixene has a large volume of distribution, indicating that it distributes extensively into tissues beyond the bloodstream.Â
MetabolismÂ
chlorprothixene undergoes extensive hepatic metabolism in the liver. The primary metabolic pathway involves oxidation, followed by glucuronidation and sulfation. The enzyme CYP2D6 plays a significant role in the metabolism of chlorprothixene. Some metabolites of chlorprothixene also have pharmacological activity.Â
Elimination and excretionÂ
The metabolites of chlorprothixene are excreted through the urine and, to a lesser extent, in feces. The elimination half-life of chlorprothixene can vary among individuals but is in the range of 20 to 30 hours.Â
Administration:Â
Patient information leafletÂ
Generic Name: chlorprothixeneÂ
Pronounced: klawr-proh-THIK-seen Â
Why do we use chlorprothixene?Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
